Global Pediatric Orthopedic Implant Safety & Efficacy (Global POISE) Clinical Follow-Up Program
The purpose of this research study is to evaluate the safety and efficacy (how well they do their job) of OrthoPediatrics medical implants.
Glomerular Disease Program | NYU Langone Health
Doctors at the Glomerular Disease Program provide care for children at Hassenfeld Children’s Hospital at NYU Langone.
Glomerulonephritis in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone diagnose and treat glomerulonephritis, a condition that causes kidney inflammation.
GLP-1 Agonist Treatment for Opioid Use Disorder - A Multi-Site Randomized Placebo-Controlled Trial
The purpose of this research study is to determine whether once-weekly treatment with an investigational drug, semaglutide, may help reduce illicit opioid use compared to placebo in individuals with opioid use disorder who are receiving either buprenorphine or methadone.
Gluten-Free Diet for Celiac Disease in Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone help children with celiac disease adapt to a gluten-free diet.
Glycemic and Cardiometabolic Biomarker improvements associated with reduction in air pollution exposure
In this research, we will conduct a double-blind, sham-controlled, randomized trial to examine the glycemic and cardiometabolic impact of air pollution exposure reduction using home portable air cleaners (PACs) in a cohort of 142 adult with prediabetes. This study will not evaluate the PAC or sham as medical devices in the context of this research; rather, the PAC and sham will be used per their commercialized indication as tools to standardize the conditions in order to measure the glycemic and cardiometabolic impact of reduced air pollution exposure.
Goal-Directed Cardiopulmonary Resuscitation in Cardiac Arrest Using a Novel Physiological Target: A Pilot Mechanistic Randomized Control Trial
The proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedback CPR will be assessed. 150 adult patients who have a cardiac arrest event at NYU Tisch Hospital will be randomized to one of two treatment groups: (1) Physiological-Feedback CPR or (2) Non-Physiological (Audiovisual) Feedback CPR.
GOG-3082 - Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma Endometrial Adenocarcinoma and Urothelial Carcinoma Based on Acrivon OncoSignature Status
This is a clinical study to test a drug called ACR-368 (also known as Prexasertib) for the treatment of ovarian, endometrial, and urothelial cancer that has returned and is resistant to platinum-based chemotherapy. The study will test ACR-368 on its own and in combination with a low-dose chemotherapy drug called Gemcitabine. Patients will be selected for the study based on the results of a test called OncoSignature (a patient selection tumor biopsy test), which will predict how effective ACR-368 will be for each patient. Patients will be allocated to one of two groups based on their OncoSignature result: Arm 1 for patients with a positive OncoSignature result and Arm 2 for patients with a negative or inconclusive OncoSignature result. In Arm 1, patients with a positive OncoSignature result will receive ACR-368 alone in a Phase 2 study. In Arm 2, patients with a negative or inconclusive OncoSignature result will receive a combination of ACR-368 and low-dose gemcitabine in a Phase 1b study to determine the safe and recommended dose of the combination. A Phase 2 study will then test the combination for effectiveness and safety in each cancer type.
Golf Lab | NYU Langone Health
The Golf Lab at NYU Langone’s Sports Performance Center helps golfers improve their game and avoid injury.
Gout Treatment Center | NYU Langone Health
Experts at NYU Langone’s Gout Treatment Center care for people with gout and other crystal-induced arthritis.